# Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

> **NCT00334074** · PHASE2 · COMPLETED · sponsor: **Baylor Research Institute** · enrollment: 30 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes
- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Clofarabine and Cytarabine

## Key facts

- **NCT ID:** NCT00334074
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-02
- **Final completion:** 2008-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334074, "Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00334074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*